Holen Sie sich die Stockscreener-App
3.70
0.00%
0.00
Vorhandelsmarkt:
3.99
0.29
+7.84%
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth ... - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Fulcrum Therapeutics (FULC) Stock Price, News & Analysis - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum (FULC) Issues Strategic Employee Stock Options PackageKey Details Revealed - StockTitan
FULCFulcrum Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of "Hold" by Brokerages - MarketBeat
Rare Disease Pioneer Fulcrum Takes Center Stage at Major Healthcare Conference - StockTitan
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average PT from Brokerages - Defense World
Fulcrum Therapeutics Insider Ups Holding During Year - Yahoo Finance UK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Acquires 97,565 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics Advances Pociredir for Sickle Cell Disease - TipRanks
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.33 - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in F - GuruFocus.com
Geode Capital Management LLC Raises Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Barclays PLC Boosts Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Stifel Financial Corp Decreases Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat
State Street Corp Increases Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
State Street Corp Boosts Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Fulcrum Therapeutics jumps amid takeover speculation - MSN
Fulcrum Therapeutics Receives Termination Notice from Sanofi Ending Collaboration Agreement for Losmapimod - Defense World
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump - Simply Wall St
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - Marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago - Yahoo Finance
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Charles Schwab Investment Management Inc. Acquires 393,202 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics' SWOT analysis: stock faces headwinds after trial setback - Investing.com
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):